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PREVALENCE AND PREDICTORS OF CHRONIC LIVER DISEASE IN AN
URBAN HIV POPULATION. Sunanda M. Pejavar, Timothy J. Henrich, Naudia
Lauder, Nicole Forbes, Krystn Wagner, Jose Salvana, Sharon Weissman, Pamela E.
Jackson, Amanda Durante, and Andre N. Sofair. Department of Internal Medicine, Yale
University, School of Medicine, New Haven, CT.
Chronic liver disease (CLD) is a leading cause of morbidity and mortality in HIVinfected individuals. The purposes of this study were to determine the prevalence and
etiologies of CLD in an urban HIV-infected population and to identify CLD risk factors.
We conducted a retrospective chart review of 799 HIV-infected patients seen at four New
Haven health centers from 2002 to 2003. We applied the New Haven County Liver
Study definition to identify patients with CLD. 65% were male, 44% were African
American, and 23% were of Hispanic ethnicity. The mean age was 45 years. 30% had a
history of alcohol abuse. 35% reported injection drug use as their HIV risk factor.
Heterosexual contact and men having sex with men (MSM) were reported in 31% and
16% of cases. 50% of patients had a diagnosis of AIDS. 60% percent of patients had
CLD. Over 50% of cases of CLD were attributed to chronic hepatitis C (HCV), either
alone or with coexisting alcoholic liver disease. Alcoholic liver disease alone, hepatitis B
virus (HBV), HAART-induced liver disease, and non-alcoholic liver disease (NAFLD)
accounted for smaller percentages. 84% of patients were on HAART, but only 3.6% of
patients with positive HCV or HBV serologies were on treatment for CLD. 75% of
patients received pneumococcal and influenza vaccines, but only half of eligible patients
received hepatitis A and B vaccines. In multivariate analysis, alcohol abuse and positive
HCV status were associated with CLD. CLD is prevalent in our population. Preventive
care and treatment for CLD are being overlooked in many. Vaccines, treatment for viral
hepatitis, and strategies for reducing drug and alcohol abuse are priorities.
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1
INTRODUCTION

I. Epidemiology of HIV and AIDS
An estimated 1,039,000 to 1,185,000 persons in the United States are currently
living with HIV/AIDS, including 250,000 to 320,000 who are unaware of their serostatus
[1]. Each year, approximately 40,000 new HIV infections occur, 70% of which occur
amongst men, although a growing number of women are affected yearly [2]. Men who
have sex with men (MSM) currently represent the largest proportion of cases by
transmission category on both national and state-wide levels (49% in 2003), but
heterosexuals and intravenous drug users are also significantly affected (34% and 19%,
respectively in 2003) [2].
In the absence of treatment, HIV progresses to full-blown AIDS in the majority of
individuals. It is estimated that 10 to 12 percent of HIV-infected patients progress to
AIDS within the first 5 years following infection, and over 50% develop AIDS within 10
years [3,4] Approximately five percent of individuals have stable CD4+ T cell counts
and no symptoms even after 12 or more years [5].

The progression from HIV to

untreated AIDS is recognized as being universally fatal. Only a very small percent of
people with untreated AIDS survive five years after they are diagnosed.
Reports by the CDC have documented steep declines in AIDS mortality within
the United States over the last decade (from 50,000 deaths per year in 1995 to 16,000 in
2004 [2,6]. This trend is mostly attributed to the advent of potent antiretroviral therapy,
which gained widespread acceptance and use in the mid 1990s. In recent years, however,

2
the rate of decline has slowed, due to emerging problems such as unequal access to HIV
care, incomplete adherence to therapeutic regimens, and viral resistance to therapy.
The distribution of HIV and AIDS cases by demographic characteristics has also
changed substantially over time. The disease disproportionately affects ethnic minorities,
such as African Americans and Hispanics, women, and adolescents, and recent studies
have shown that infection and mortality rates are in fact increasing within several subsets
of these populations.

The largest proportional increase in new cases has occurred

amongst heterosexual women, from approximately 9% in 1992 to 27% in 2003. In
addition, the proportion of cases in African Americans has increased from 25% to 50% of
the total and that of Hispanics has increased 14% to 20% over two decades. Minority
Americans currently represent the majority of new cases (71%), as well as the largest
proportion of people living with AIDS (64%).

This puts certain populations, such as

minority MSM and minority women at particularly high risk [2, 6-10].

II. Epidemiology of Chronic Liver Disease (CLD)
Chronic liver disease (CLD) is one of the ten leading causes of mortality in the
United States, and accounts for over 25,000 deaths each year [11,12]. Although overall
mortality from CLD has shown a gradual decline over the last three decades, death rates
within certain subgroups have increased over time. For example, CLD deaths attributable
to hepatitis C increased 220% between 1993 and 1998, while mortality from other causes
of CLD decreased or remained unchanged over the same time period [12]. Cirrhosis and
CLD also disproportionately affect men, certain ethnic minorities, and the middle-aged
population. In fact, CLD ranks as the fifth leading cause of death in men between the
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ages of 45 and 64 years, and accounts for more than twice as many deaths amongst
Native Americans, Hispanics, and African Americans than other ethnic groups [11].
Alcohol and viral hepatitis are considered the two most important etiologies for CLD;
however, NAFLD (non-alcoholic fatty liver disease) is increasingly being recognized as a
common cause. Risk factors for chronic liver disease include low socioeconomic status,
drug use, exposure to environmental and industrial toxins, and genetic predisposition.
Alcohol use is one of the most significant causes of chronic liver disease in the
United States.

Alcoholic liver disease can be classified into three distinct, often

overlapping histologic categories: steatosis, acute alcoholic hepatitis, and cirrhosis.
While steatosis is often asymptomatic and thought to be reversible with abstinence,
hepatitis is much more severe, with up to 80% of patients progressing to cirrhosis or
hepatocellular carcinoma upon continued ingestion of alcohol [13]. There is a direct
correlation between alcohol consumption and liver-related mortality [14]. Of the 14
million Americans who meet criteria for alcoholism, 2 million are suspected of having
significant liver disease. It is estimated that men who drink more than 80 g/d of ethanol
for several years will be at substantial risk of developing clinical liver disease [15].
Women who ingest a similar amount are up to four times more likely than men to
develop alcoholic liver disease, and they exhibit a tendency to progress to cirrhosis even
with abstinence [16,17].
Hepatitis C virus is the single most common cause of chronic liver disease, and
poses a significant public health problem in the United States and worldwide. Infection
with HCV causes chronic hepatitis in 80% of patients, and up to 25% of monoinfected
individuals develop cirrhosis and end-stage liver disease within the next thirty to forty
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years [18]. Chronic liver disease from HCV infection is currently the most common
indication for liver transplantation, accounting for up to 35% of orthotopic transplant
recipients [19]. Although treatment response varies by genotype, treatment for HCV
genotype 1 (the genotype that infects the vast majority of individuals) has thus far been
rather disappointing, with the best response rates to interferon and ribavirin reported at
40% [20, 21]. Alcohol use and HCV infection frequently coexist in patients, and many
studies have shown that their effects are synergistic in promoting liver damage, hastening
both cirrhosis and hepatocellular carcinoma [22,23].
Although the development of the hepatitis B vaccine in the mid-1980’s is
considered one of the major achievements of modern medicine, HBV infection remains
an important cause of morbidity and mortality worldwide. One analysis found that the
rate of HBV-related hospitalizations, cancers, and deaths in the United States had more
than doubled over the last decade [24]. The manifestations of chronic HBV infection
range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and
hepatocellular carcinoma. Long term studies have shown that the majority of individuals
who are HbsAg positive remain asymptomatic [25]; however, there is still approximately
a 15% lifetime risk of developing cirrhosis or hepatocellular carcinoma [26].

Like

HCV, treatment for HBV has been suboptimal, which may be complicated by the fact
that infected patients often have comorbid disease such as chronic HCV infection and
alcoholic hepatitis.
The prevalence and risk factors for NAFLD are not well-described, although it is
a condition currently under active investigation. NAFLD is frequently associated with
obesity, insulin resistance, type 2 diabetes mellitus, and hyperlipidemia. In unselected
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populations, the prevalence is reported to range between 3 and 23 percent [27, 28];
however, in patients with diabetes, the prevalence may be as high as 63% [29].
Symptomatic NAFLD is extremely uncommon, but there remains a small risk of
cirrhosis, hepatocellular carcinoma, and mortality from end stage liver disease, reported
in retrospective studies as occurring in fewer than 3% of patients with NAFLD [30].

III. Relationship between CLD and HIV
Since the introduction of HAART, the life expectancy of patients with HIV has
dramatically increased [31, 32]. The use of HAART has led to declines in opportunistic
infections and acute bacterial infections, both of which were implicated in the majority of
AIDS-related deaths during the pre-HAART era. As a result of increased longevity,
mortality and morbidity due to other co-existing conditions, such as liver cirrhosis, renal
failure, cardiac disease, and cancer, are assuming greater importance.
End-stage liver disease in particular has become a leading cause of death amongst
HIV-infected patients, accounting for up to 50% of deaths amongst hospitalized HIV
positive patients [33]. Most etiologies of liver disease in these patients are similar to
those in the general population, such as chronic HCV, chronic HBV, and alcoholic
hepatitis. However, the high risk of hepatotoxicity from antiretroviral drugs and the
effects of immunosuppression on the natural courses of these diseases present additional
challenges in HIV-infected patients.
Due to the shared route of transmission, coinfection with HCV and HIV has
become an especially common diagnosis, reported to affect up to 30% of all HIV-infected
patients [34]. Coinfection is particularly prevalent in IV drug users, whose rates of
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coinfection may range from 75% to 90% [35-37]. Several studies have established that
HIV infection modifies the natural history of HCV infection, accelerating the progression
from chronic hepatitis to cirrhosis and end-stage liver disease and placing HIV-positive
patients at increased risk for morbidity and mortality secondary to these conditions. [33,
38-41]. The effect of HCV infection on the natural history of HIV, however, is a much
more controversial issue and results have been conflicting thus far. While some studies
suggest that certain HCV genotypes or higher HCV viral loads are associated with more
rapid progression to AIDS or death [42-44], others detect no correlation between HCV
infection and progression of HIV [45-47].
Like HCV, hepatitis B virus is transmitted through blood and body fluids, and
therefore may be found in HIV-infected populations. In the absence of treatment for
HBV, there is an increased frequency of cirrhosis in coinfected patients compared with
HIV or HBV-monoinfected patients [48, 49].

Liver-related mortality in HIV/HBV

coinfection is reported to be 14-fold higher than that for either virus alone, and patients
who have HIV are three to six times more likely to develop chronic hepatitis B following
occult infections compared with patients who do not have HIV [50]. There are several
medications, such as lamivudine and tenofovir, which are approved to treat both HIV and
HBV.
Although clinical manifestations of liver toxicity are somewhat rare from
antiretroviral therapy alone, mild to moderate elevations in liver transaminases (AST and
ALT) are relatively common in patients on HAART. Chronic viral hepatitis, alcohol
ingestion, and use of other drugs are co-factors that increase the incidence of elevated
hepatic markers in HIV patients. Several studies have, furthermore, suggested that HCV
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increases the risk of hepatotoxicity from antiretroviral regimens [51, 52], which
complicates the fact that suppression of HIV viral load in coinfected patients may
decrease the rate of HCV progression [53]. This is particularly true nevirapine, full-dose
ritonavir, and tipranavir, which are associated with increased risk of hepatotoxicity in
coinfected patients.

Although the overwhelming evidence supporting the benefit of

antiretroviral therapy indicates that HAART should not be withheld in coinfected
patients, liver injury may be one of the major limiting factors in the effectiveness of
therapy.
Alcohol abuse frequently coexists with HIV, and may play a significant role in
determining patient outcome.

Alcoholism is associated with greater mortality and

morbidity, increased symptom burden, poorer compliance with antiretroviral therapy,
more rapid progression of disease, increased severity of comorbid disease (particularly
chronic HCV infection), and greater risk of viral resistance [54-57]. Because alcohol
abuse, HCV, and HBV may often act synergistically in accelerating liver damage, HIVinfected patients with multiple risk factors for chronic liver disease are at particular risk
for liver-related morbidity and mortality.
Risk factors for steatohepatitis in the non-HIV population are also valid in
individuals with HIV. However, HIV-infected patients who are treated with NRTIs and
d4T in particular may be especially prone to severe macrosteatosis. Protease inhibitors
(PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) appear to act synergistically
in development of HIV-related lipodystrophy, and the length of therapy with these
medications positively correlates with the amount of lipodystrophy [58]. Consequently,
HIV-positive patients on HAART tend to have a higher incidence of insulin resistance
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and visceral abdominal obesity. Furthermore, insulin resistance and the incidence of
lipoatrophy are increased significantly in patients with HIV/HCV coinfection compared
with those with HIV alone, which may also predispose to NAFLD and lead to hepatic
fibrosis [59].

9
SPECIFIC AIMS

The burden of chronic liver disease is considerable in HIV-infected patients; however,
very few studies have described this phenomenon in an entire urban HIV population.
Therefore, the purposes of this study were:
1. To calculate the prevalence and etiologies of chronic liver disease in urban
HIV clinics.
2. To identify risk factors associated with an increased risk of chronic liver
disease in this population.
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METHODS

Subjects. This study is a retrospective chart review of HIV-infected patients followed at
four different urban health centers in New Haven (Nathan Smith Clinic, Hill Health
Center, St. Raphael’s Hospital/Haelen Center, and Fair Haven Clinic and Health Center).
Patients were included if they were HIV seropositive, and had attended clinic between
2002 and 2003; abstracted data, however, was not limited to this twelve month period but
also included information prior to 2002 and following 2003. Any data that was dated
past January 1, 2006 was not abstracted. A 50% random sample was used at Nathan
Smith Clinic and the St. Raphael’s Hospital/Haelen Center, while 100% samples were
included from the other sites. The chart review was started prior to my involvement in
the study; therefore, most of the abstraction at Hill Health Center and Fair Haven Clinic
was carried out by other individuals, while abstraction at Nathan Smith Clinic and Haelen
Center was completed by me.

Data Collection. Data were abstracted from the patient charts by trained individuals
using a standard data collection form; charts were in the form of either computerized or
paper records depending on site. Abstracted data included demographic characteristics,
such as age, gender, race/ethnicity, height, weight, and town of residence; social practices
such as HIV exposure and alcohol abuse; clinical and laboratory data regarding liver
function, HIV progression, hepatitis and HIV serology, vaccinations (hepatitis A and B,
pneumococcal, and influenza), and treatment history. Alcohol abuse was defined as
alcohol intake of > 3 drinks per day for 10 years, hospitalization or rehabilitation,
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withdrawal, history of DUI, or physician impression of alcoholism. Liver-related clinical
data consisted of biopsy results, clinical events (hepatic encephalopathy, variceal bleed,
ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, or cholangitis),
and diagnostic imaging results (US, CT, MRI, liver/spleen scan, or endoscopy). In
addition, liver transaminases (AST, ALT, alkaline phosphatase, and GGT), iron studies,
and triglycerides were recorded (first, last, and all abnormal tests ≥ 6 months apart).
HIV-related data included immunologic markers recorded at intervals of ≥ 6 months
(CD4, viral load, WBC, % lymphocyte) and diagnosis of AIDS, based on AIDS-defining
illnesses (ADIs) or CD4 count. ADIs were defined according to the CDC 1993 revised
classification system [60].

Treatment for chronic liver disease (CLD), as well as

antiretroviral medication history, was recorded.

Abstracted information for CLD

included treatment regimen (standard interferon alfa, pegylated interferon alfa, ribavirin,
lamivudine, adefovir, or Cellcept), length of treatment, reason for discontinuation, and
treatment response (ETR and SVR). Data regarding antiretroviral medication included
drug name, dose, and duration of use.

Assessment of CLD. Patient charts were screened for evidence of CLD using the New
Haven County Liver Study (NHCLS) case definition. This study defines chronic liver
disease as: two sets of abnormal LFTs (elevated ALT, elevated AST, or concurrently
elevated alkaline phosphatase and GGT) ≥ 6 months apart, a liver-related clinical event
(hepatic encephalopathy, variceal bleed, ascites, or SBP), a diagnostic imaging result
indicating chronic hepatitis, cirrhosis, or hepatocellular or cholangiocarcinoma, or a
biopsy result consistent with chronic hepatitis, cirrhosis, or hepatocellular or
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cholangiocarcinoma. The classification of cirrhosis was made if biopsy showed features
consistent with cirrhosis, or if diagnostic imaging studies showed positive signs such as
nodular/shrunken liver, portal hypertension, colloid shift, ascites, varices/collaterals,
and/or cirrhosis. In those patients who satisfied the case definition for CLD, a diagnostic
impression of etiology was made based on clinic notes and laboratory data. Etiologies
included alcoholic liver disease (based on classification of alcohol abuse), chronic
hepatitis B, chronic hepatitis C, HIV antiretroviral induced liver disease, or NASH/fatty
liver. Chronic hepatitis B was defined as positive HBV sAg or positive HBV eAg on
serology. Chronic hepatitis C was defined as positive ELISA, RIBA, or PCR. “Possible”
HCV infection was defined as positive ELISA or RIBA results, without quantitative or
qualitative PCR results or genotype results. “Definite” HCV infection was identified as
positive PCR or HCV genotype results. Patients could be classified as having more than
one etiology.

Assessment of Clinical Care. Markers of clinical care included treatment for CLD and
HIV, gastroenterology referrals, and vaccination history. Because CLD treatment was
defined as antiviral therapy, only patients with evidence of HCV infection or HBV
infection were included in this analysis. Patients included in HAV or HBV vaccination
analysis were those who did not have serological evidence of chronic disease or previous
immunity. Only one dose of each vaccine was required to qualify a patient as having a
positive vaccination history.

13
Statistical Analysis. Descriptive statistics were expressed as means and percentages for
continuous and categorical variables, respectively. CLD was the outcome measured in all
analyses; univariate chi-squared tests were used to determine predictors.

Baseline

variables examined were age (dichotomous variable expressed as >/=mean age or <mean
age); gender; race (white, African-American, or other); ethnicity (Hispanic/Latino or not
Hispanic/Latino); HIV risk factor (IDU, MSM, IDU/MSM, heterosexual contact, or
other); alcohol abuse; CD4 count (dichotomous variable expressed as <200 or >/=200);
viral load (dichotomous variable expressed as <10,000or >/=10,000); infection with
HCV; use of antiretroviral therapy; and AIDS diagnosis.

Liver function test abnormalities were examined in several different ways. For patients
who were on HAART and had AST or ALT values recorded before and after initiation of
treatment, “pre-HAART” and “post-HAART” values were recorded. The pre-HAART
values were those that were closest to initiation of HAART; these were defined as that
patient’s baseline LFTs. The post-HAART values were the highest values recorded
following initiation of HAART. The means of these pre-HAART and post-HAART
values, as well as the mean percent change (delta), was described. The mean values and
deltas were also expressed as function of whether patients had CLD or chronic HCV
infection.

HIV-related tests (CD4 count and viral load) were only used in statistical analyses if they
were recorded prior to initiation of HAART or in the absence of antiretroviral therapy.
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RESULTS

Data from a total of 799 patients were reviewed (262 patients from Nathan Smith
Clinic; 244 patients from Hill Health Center; 237 from St. Raphael’s Hospital/Haelen
Center; and 56 from Fair Haven Clinic and Health Center). Demographic characteristics
of the study population are shown in table 1, both as a whole and separately by clinic.
The majority of patients were male (65%) and African-American (44%), and these
TABLE 1: DEMOGRAPHIC CHARACTERISTICS

Gender (%)

Male
Female
Transgender
Unknown

Age (mean; years, range)

ALL PTS*
(N=799)

NSC
(N=262)

HHC
(N=244)

HC/HSR
(N=237)

FHCHC
(N=56)

64.7
34.0
0.6
0.7

61.1
37.0
1.1
0.8

70.9
27.5
0
1.6

62.5
37.1
0.4
0

62.5
35.7
1.8
0

45.9
(26-75)
19.9
29.8
0
5.3
45.0

43.5
(8-67)
10.3
58.2
0.8
0.4
30.3

45.8
(28-81)
32.1
50.2
0.8
1.3
15.6

40.0
(9-62)
14.3
23.2
0
1.8
60.7

Race (%)

White
Black
Asian
Other
Unknown

44.7
(8-81)
20.1
44.1
0.5
2.4
32.9

Ethnicity (%)

Hispanic/Latino
Not Hispanic/Latino
Unknown

22.7
51.9
25.4

14.9
17.2
67.8

28.3
68.9
2.8

16.5
76.3
7.2

60.7
37.5
1.8

Town (%)

New Haven
New Haven County
Non-New Haven County
Unknown

61.6
19.9
6.9
11.6

37.0
20.2
15.7
27.1

82.0
10.6
0.4
7.0

62.0
31.2
4.7
2.1

85.7
10.7
3.6
0

Alcohol
Abuse (%)

Yes
No
Unknown

30.4
59.0
10.6

24.8
64.1
11.1

34.4
59.0
6.6

32.9
50.6
16.5

28.6
69.6
1.8

*NSC = Nathan Smith Clinic (Yale New Haven Hospital)
HHC = Hill Health Center
HC/HSR = Haelen Center (Hospital of St. Raphael)
FHCHC = Fair Haven Clinic and Health Center

15
findings were consistent across all four clinics. At Hill Health Clinic and Haelen Center,
over 50% of patients were African-American. The mean age was 45 years. Overall,
approximately 23% of patients were found to be of Hispanic or Latino heritage, although
there were many patients for whom ethnicity was not reported. Ethnicity varied widely
by clinic, with Fair Haven Clinic having the largest proportion of Hispanic/Latino
patients (61%). Although the majority of patients from all health centers were from New
Haven (62%), Nathan Smith Clinic had the largest percentage of patients from outside
New Haven County. This finding is consistent with the fact that Nathan Smith Clinic is a
university affiliate and therefore likely to receive a substantial number of referrals.
Approximately 30% of patients were found to have a history of alcohol abuse.
Table 2 summarizes HIV-related characteristics. The majority of patients in this
study population acquired HIV through intravenous drug use (35%); at Hill Health
Center, IDU made up over 50% of cases by transmission category. Heterosexual contact
and MSM were also major sources of HIV exposure, accounting for 31% and 16% of
cases, respectively. The mean pre-HAART CD4 count in this population was 296, and
the mean pre-HAART viral load was 116,233. Over half of all patients were diagnosed
with AIDS, and of these, most qualified by having a CD4 count of 200 or below or by
having both an AIDS-defining illness as well as a CD4 count under 200.
Liver-related characteristics are recorded in table 3. About 60% of patients met
the CLD case definition; of these, the majority qualified by having two sets of abnormal
LFTs six months apart. Of note, 84% of all patients were found to have abnormal LFTs
at some point in their clinical care; however, only 57% of these met the CLD case

16
TABLE 2: HIV CHARACTERISTICS

HIV Exposure (%)

IDU
MSM
MSM/IDU
Heterosexual
Other
Unknown
CD4 count (mean, range)*
Viral load (mean, range)†
AIDS (%)

Yes
CD4 count
ADI°
Both
Unknown
No
Unknown

ALL PTS
(N=799)

NSC
(N=262)

HHC
(N=244)

HC/HSR
(N=237)

FHCHC
(N=56)

34.5
16.2
1.0
31.3
0.8
16.2
296
(1-1520)
116233
(1-4100K)
52.2
50.8
6.5
36.7
6.0
43.4
4.4

32.8
17.6
0.4
27.1
1.5
20.6
292
1-1520)
104796
(50-750K)
49.2
53.5
8.5
30.2
7.8
44.3
6.5

50.4
7.8
2.1
22.9
0
16.8
307
(2-1155)
78262
(50-1380K)
51.6
54.8
3.2
30.9
11.1
46.7
1.7

23.6
22.4
0.4
43.0
0
10.6
274
(2-1163)
187026
(50-4100K)
59.5
45.4
7.8
46.8
0
35.0
5.5

19.6
19.6
1.8
37.5
3.6
17.9
368
(1-1391)
87817
(400-817K)
37.5
47.6
4.8
42.8
4.8
60.7
1.8

*CD4 count included only if patient had values recorded prior to ART;
N=666 (all), N=246 (NSC), N=195 (HHC), N=181 (HC/HSR), N=44 (FHCHC)
†Viral load included only if patient had values recorded prior to ART;
N=603 (all), N=224 (NSC), N=183 (HHC), N=152 (HC/HSR), N=44 (FHCHC)
°AIDS-defining illness

TABLE 3: LIVER-RELATED CHARACTERISTICS

CLD case
definition (%)

HCV Status (%)

HBV Status (%)
LFTs†
(mean values, range)

ALL PTS
(N=799)

NSC
(N=262)

HHC
(N=244)

HC/HSR
(N=237)

FHCHC
(N=56)

Yes
Biopsy*
Imaging*
Clinical Event*
LFTs*
No
Unknown
Positive
Definite
Possible
Negative
Unknown
Positive
Negative
Unknown
Baseline pre-ART ALT
Baseline pre-ART AST

59.7
8.4
13.9
3.9
94.1
38.8
1.5
39.8
56.3
43.7
52.8
7.4
4.8
83.6
11.6
46 (4-636)
52 (5-688)

57.6
15.9
20.5
5.3
94.7
42.4
0
42.4
64.0
36.0
48.9
8.8
5.3
85.1
9.5

65.2
2.5
8.8
3.8
96.2
34.8
0
44.7
56.9
43.1
43.8
11.5
3.7
78.3
18.0

57.8
8.1
14.8
3.4
90.6
37.1
5.1
34.2
53.1
46.9
63.7
2.1
6.3
84.4
9.3

53.6
3.3
3.3
0
96.7
46.4
0
30.4
17.6
82.4
64.3
5.4
0
96.4
3.6

Baseline post-ART ALT
Baseline post-ART AST

65 (2-638)
73 (7-998)

*Patients may qualify for CLD case definition by more than one criteria.
†Significance testing revealed that p<0.0001 between mean pre-HAART and mean post-HAART LFTs.
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definition through the more stringent LFT criterion. Forty percent of patients were HCV
positive by serology, and of these patients, 56% were categorized as having “definite”
infection (PCR or genotype results) while the rest had only ELISA or RIBA results and
were therefore classified as having “possible” infection. Over 81% of patients with a
history of intravenous drug use tested positive for HCV, whereas only 11% of men who
have sex with men and 17% of patients with heterosexual HIV risk factors had positive
HCV serologies (data not shown). Only about 5% of patients had chronic HBV by
serology. Mean baseline pre-HAART ALT and AST were significantly lower than mean
baseline post-HAART ALT and AST (p<0.0001).
Table 4 describes the etiologies for CLD in the subset of patients who met the
NHCLS case definition. Greater than 50% of patients had chronic liver disease as a
result of hepatitis C, either alone or with coexisting alcoholic liver disease. Alcoholic
liver disease alone made up a substantial proportion of the total number of patients with

TABLE 4: CLD ETIOLOGY

HCV
HCV/Alcohol
Alcohol
HBV/HCV
HBV
NASH
HAART-induced liver disease
Alcohol/HBV
HCV/HAART
HCV/NASH
Alcohol/HCV/HBV
Alcohol/HAART
HBV/HAART
Other
Unknown

ALL PTS
(N=488)

NSC
(N=151)

HHC
(N=159)

HC/HSR
(N=147)

FHCHC
(N=31)

40.8
10.3
8.6
3.5
2.3
2.1
1.6
1.0
1.0
0.8
0.4
0.4
0.4
3.0
23.8

37.8
11.9
4.0
6.6
1.3
1.3
0
2.0
0
2.6
0
0
0
4.0
28.5

55.4
5.0
7.6
1.9
2.5
0.6
3.1
0
2.5
0
0
0
1.3
4.4
15.7

27.9
15.7
14.3
0
2.7
4.8
0.7
1.3
0
0
1.3
0.7
0
0
26.6

41.9
3.2
9.7
3.2
3.2
0
6.5
0
3.2
0
0
3.2
0
6.5
19.4
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CLD (8.6%), but the percentage varied widely by clinic (4% to 14.3%). Although HBV
alone only accounted for 2.3% of the total population, a number of patients were
coinfected with HBV and HCV. Other etiologies for chronic liver disease (including
HAART-induced liver disease and NAFLD) accounted for smaller percentages; however,
almost 18% of patients were found to have more than one etiology for their liver disease.
Table 5 summarizes the clinical care provided to this study population.
Approximately 84% of patients were treated with HAART; however, only a very small
percentage of patients who were HCV or HBV positive underwent treatment for CLD

TABLE 5: CLINICAL CARE
ALL PTS
(N=799)

NSC
(N=262)

HHC
(N=244)

HC/HSR
(N=237)

FHCHC
(N=56)

Yes
No
Yes
No
Yes
No
Unknown

83.5
16.5
3.6
96.4
3.7
93.9
2.34

79.0
20.0
8.4
91.6
2.7
96.6
0.7

79.5
20.5
0.9
99.1
6.6
92.2
1.2

91.1
8.9
1.1
98.9
5.9
94.1
0

89.3
10.7
0
100
12.5
87.5
0

Yes
No
Unknown

74.6
19.4
6.0

53.0
44.3
2.7

80.3
9.4
10.3

87.8
5.5
6.7

94.6
5.4
0

Influenza

Yes
No
Unknown

77.7
16.2
6.1

71.4
26.0
2.6

72.1
17.6
10.3

87.3
5.5
7.2

91.1
8.9
0

Hepatitis A†

Yes
No
Unknown

N=346
50.9
36.7
12.4

N=126
41.3
57.1
1.6

N=82
31.7
54.9
13.4

N=120
74.2
0.8
25.0

N=18
50.0
50.0
0

Hepatitis B†

Yes
No
Unknown

N=317
49.2
26.2
24.6

N=94
44.7
51.1
4.2

N=95
60.0
29.5
10.5

N=95
32.6
2.1
65.3

N=33
78.8
15.1
6.1

HAART (%)
CLD treatment (%)*
Gastroenterologist (%)
Vaccines (%)
Pneumococcal

*Patients only included if they were HCV positive (both “possible” and “definite”) or HBV positive;
N=338 (all), N=119 (NSC), N=112 (HHC), N=90 (HC/HSR), N=17 (FHCHC)
†Patients were only included if they did not have evidence of current infection or prior immunity.
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(3.6%). Treatment for CLD varied significantly by clinic, with the largest percentage
(8.4%) being treated at Nathan Smith Clinic. Gastroenterology referrals were provided to
between 2.7% and 12.5% of patients, depending on clinic. With respect to vaccination
history, 75% and 78% of patients had documented receipt of pneumococcal and influenza
vaccines, respectively. However, only about half of patients who did not have evidence
of chronic HAV or HBV infection or previous immunity received vaccinations against
these pathogens. The history of vaccination varied widely depending on specific clinic;
at Haelen Center, almost three-fourths of patients received the hepatitis A vaccine, and at
Fair Haven Clinic, approximately 79% of patients were vaccinated against hepatitis B.
In table 6, antiretroviral therapy and liver function tests are compared in patients
who either do or do not meet the CLD case definition, as well as in patients who do or do
not have serological evidence for chronic HCV infection. The proportion of patients on
ART was similar in the group of patients that meet the case definition for CLD as in
those who do not. The mean post-HAART LFTs were significantly higher than the mean
pre-HAART LFTs in patients who had CLD (p<0.0001), as well as in patients who were
HCV positive (p<0.0001).

TABLE 6: LIVER-RELATED CHARACTERISTICS FOR SUBSETS
CLD

No CLD

HCV

No HCV

ART

Yes
No

(N=477)
86.4
13.6

(N=310)
80.0
20.0

LFTs†

Baseline pre-ART ALT
Baseline pre-ART AST

55.4
61.6

29.9
34.4

59.1
68.3

38.6
41.8

Baseline post-ART ALT
Baseline post-ART AST

81.6
91.0

35.0
40.6

87.9
103

51.0
54.3

†Significance testing revealed that p<0.0001 between mean pre-HAART and mean post-HAART LFTs for
patients with CLD, as well as patients with HCV.
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The results of univariate chi-squared analysis are shown in table 7. Mean age
greater than or equal to 45 years; male gender; history of alcohol abuse; HIV risk factor
of MSM, intravenous drug use, or heterosexual contact with an HIV-positive individual;
positive HCV status (and, more specifically, positive PCR or genotype results); treatment
with HAART; and diagnosis of AIDS were all significantly associated with an increased
risk of chronic liver disease by the NHCLS case definition. Multivariate analysis was
performed using four different models and is shown in Table 8. The first model included
all patients and found alcohol abuse and HCV status to be the only significant
independent risk factors for CLD. The second model looked at predictors of CLD in
patients with HCV alone and found that treatment with HAART was the only significant
risk factor. The last two models included patients with “definite” HCV and patients with
neither HCV or HBV, respectively; none of the risk factors were significant.
TABLE 7: PREDICTORS OF CLD (UNIVARIATE)
Age
Gender
Alcohol Abuse
HIV Risk Factor
HCV status
HCV category
ART
AIDS
Race
Ethnicity
CD4 count
Viral Load

Age >45 yrs
Male
Positive
MSM
IDU
Heterosexual Contact
Positive
Definite
Yes
Yes

p = 0.01
p = 0.006
p < 0.001
p < 0.001
p <0.001
p <0.001
p < 0.001
p < 0.001
p = 0.018
p = 0.032
p = 0.595
p = 0.420
p = 0.728
p = 0.611

TABLE 8: PREDICTORS OF CLD (MULTIVARIATE)
MODEL
Model 1

INCLUSION CRITERIA
All patients

Model 2
Model 3
Model 4

HCV-positive patients
“Definite” HCV infection
Patients with no HCV or HBV infection

PREDICTORS
Alcohol abuse
HCV status
ART
none
none

P-VALUES
p = 0.02
p < 0.0001
p = 0.03
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DISCUSSION

In this large, urban cohort of HIV-infected patients in New Haven County, we
observed a high prevalence of chronic liver disease. Sixty percent of individuals in our
study population qualified as having CLD according to the New Haven County Liver
Study case definition. The most common causes of CLD were chronic hepatitis C and
alcoholic liver disease, which together accounted for almost 60% of percent of cases.
These findings are in agreement with prior studies, which have reported similar
conclusions regarding the prevalence and etiologies for chronic liver disease in HIVinfected populations [34-37].
HIV/HCV coinfection was extremely common in our cohort. Approximately
40% of the total population was found to have positive HCV serologies, and over half of
all cases of CLD were attributed to chronic hepatitis C (with or without coexisting
alcoholic liver disease).

HCV infection was particularly common in patients who

reported a history of intravenous drug use, accounting for over 80% of this group. This
finding was similar to that in several previous studies, which reported coinfection rates of
between 75% and 90% in intravenous drug users [35-37].

Patients with positive HCV

serologies were found to have higher liver function tests than patients who were not
infected with HCV, both prior to the initiation of HAART as well as after starting
treatment.
In our study population, HAART-induced liver toxicity did not account for a
substantial proportion of cases of chronic liver disease. HAART alone was attributed to
only 1.6% of cases, but several patients had were found to have both HAART-induced
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liver disease as well as chronic viral hepatitis or alcoholic liver disease. When mean preHAART LFTs were compared with mean post-HAART LFTs, significant elevations of
approximately 50% were observed (p<0.0001). Other causes of CLD (chronic hepatitis B
and NAFLD) accounted for under 5% of all cases in our study population.
We identified several predictors of CLD in our study using univariate analysis,
including older age, male gender, history of alcohol abuse, HIV exposure (through MSM,
IDU, or heterosexual contact), positive HCV serology, treatment with HAART, and
diagnosis of AIDS. As has been reported in many previous studies, age appears to be an
important factor driving the development of chronic liver disease. Since the advent of
HAART, HIV-infected patients are enjoying greater longevity but are also more likely to
develop long-term complications from chronic disease. In our cohort, male gender was
also significantly associated with risk of CLD. This could be due to the fact that alcohol
abuse was more common in men; we found that 41% of males had a history of alcohol
abuse, compared with only 22% of females. Additionally, men have a worse long-term
prognosis with HCV infection. Regarding HIV exposure, intravenous drug use was
likely associated with CLD due to shared routes of transmission between HIV and HCV.
AIDS diagnosis was found to be a predictor of CLD, which suggests that the extremely
immunocompromised state in these patients renders them more susceptible to comorbid
disease. As expected, our study also confirmed that alcohol abuse and positive HCV
serology were strong predictors of chronic liver disease. Although HAART was found to
be a predictor of CLD, it is possible that age acted as a confounding factor, as the mean
age of patients on HAART was slightly higher that that of patients not on HAART (45
years versus 43 years).
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In multivariate analysis, we found that alcohol abuse and HCV status remained
significant independent risk factors for CLD in all patients. When we looked at patients
with HCV infection only, we found that HAART remained as the only significant
predictor of CLD. It can be speculated that these patients might have had elevated ALT
only, which their physicians were willing to tolerate given the benefit of antiretroviral
therapy in their HIV care.
We found that preventive care and treatment for CLD were being overlooked in a
substantial proportion of patients in our study.

With regards to immunization,

pneumococcal and influenza vaccines were provided in approximately three-fourths of
patients. However, these numbers varied quite widely by clinic (53% to 95% for the
pneumococcal vaccine, and 71% to 91% for the influenza vaccine.) Vaccinations for
hepatitis A and B were provided to only half of all eligible patients, and ranged from 32%
to 74% for the HAV vaccine and 33% to 79% for the HBV vaccine depending on clinic.
Furthermore, these numbers included even those patients who had received only one dose
of these vaccines, which may not actually be sufficient to confer immunity.
The immunocompromised state that develops in HIV infection puts patients at
increased risk for morbidity and mortality from infections that can usually be prevented
by vaccination, such as pneumococcal pneumonia, influenza, hepatitis A, and hepatitis B.
As was shown in our study, many patients already have underlying liver disease caused
by HCV or alcoholic hepatitis and are at increased risk of decompensation if they are
exposed to HBV or HAV. There is also evidence that HIV-infected individuals are less
likely to clear HBV DNA and are at increased risk of chronic infection [61]. Although
concerns have been raised about the safety of vaccination in HIV-positive patients,

24
specifically the risk of activating the immune system and the potential for accelerating
HIV replication and disease progression, the benefits of vaccine administration appear to
outweigh the risks.
We also found that only a very small percentage of this population underwent
treatment for their CLD. Of the patients that had positive HCV or HBV serologies, only
3.6% were treated with interferon, ribavirin, lamivudine, adefovir, or Cellcept. Once
again, this proportion varied broadly by clinic (0% to 8.4%), with the highest percentage
of patients treated at Nathan Smith Clinic. A similarly small proportion of patients were
followed by a gastroenterologist (3.7%) for specialty care.
Our study has several limitations.

First, we admit biases derived from the

retrospective design of the study and the lack of uniform interpretation of data. We did
not interview patients, and data such as liver function tests, serologies, alcohol intake,
and imaging studies were not collected in a routine fashion. A considerable amount of
data were missing in several categories, such as race and ethnicity, since these categories
depended on individual physicians’ history and note-taking. Other categories, such as
HIV exposure, were self-reported by patients, and involved disclosure of certain lifestyle
choices, such as illicit drug use or homosexual contact. Due to the sensitive nature of
these activities and the stigmas that sometimes accompany them, patients may have
chosen to withhold their histories from their physicians. Because of underreported and
missing information, therefore, it is possible that our study underestimates the prevalence
of many population characteristics. Second, our case definition for chronic liver disease
(taken from the New Haven County Liver Study) had certain inherent limitations.
Physicians in these clinics did not routinely order imaging studies, biopsies or collection
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of liver function tests; therefore, our results may again be an underestimation of the
prevalence of chronic liver disease in this population. Third, we studied a specific
population of HIV-positive individuals in New Haven County, and our results may not be
generalizable to other locales. Finally, given the fact that post-HAART LFTs were 50%
higher than pre-HAART LFTs, the NHCLS definition may be overly sensitive in this
population and affected by the impact of ART on LFT measurements.
In conclusion, the burden of chronic liver disease in HIV-infected populations is
substantial and may even be underestimated in our study. A large number of these
patients are coinfected with hepatitis C and/or have a history of alcohol abuse, and the
majority of them are not followed by gastroenterology practices. Because HIV is known
to accelerate the progression from hepatitis to cirrhosis [38-41], treatment for HCV with
antivirals such as interferon and ribavirin must be considered a priority for coinfected
patients and should be provided at the earliest possible time. Strategies aimed at the
reduction of alcohol consumption are extremely important components of care, and
particularly relevant in patients who have a history of intravenous drug use, given that
they may be more prone to the abuse of substances. Although HAART-induced liver
toxicity has been raised as a concern in this population, the benefits of antiretroviral
therapy far outweigh the risks and should be considered in all patients.
Preventive care is also of utmost importance in this population. The United States
Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) have
made recommendations that should guide physicians in providing immunizations to HIV
positive patients.

The guidelines suggest that the pnemococcal vaccine should be

provided to all adults and children at the time when CD4 count is greatest, with a single
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revaccination after five years. Annual influenza vaccination is recommended in all HIV
positive patients, regardless of CD4 count, and routine screening and immunization
against HBV is recommended for all HIV-infected adults. With regards to the HAV
vaccine, the current guidelines state that any patient with existing chronic liver disease or
certain risk factors (chronic HBV or HCV, homosexual contact, IDU, or hemophilia)
should be vaccinated either early in the course of HIV infection or following immune
reconstitution on HAART.
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